Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors
- 31 March 1998
- journal article
- other
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 97 (12), 1129-1135
- https://doi.org/10.1161/01.cir.97.12.1129
Abstract
Background —Oxidized low-density lipoprotein (ox-LDL) causes endothelial dysfunction in part by decreasing the availability of endothelial nitric oxide (NO). Although HMG CoA reductase inhibitors restore endothelial function by reducing serum cholesterol levels, it is not known whether they can also directly upregulate endothelial NO synthase (ecNOS) activity. Methods and Results —Human saphenous vein endothelial cells were treated with ox-LDL (50 μg/mL thiobarbituric acid reactive substances 12 to 16 nmol/mg) in the presence of HMG CoA reductase inhibitors simvastatin and lovastatin. In a time-dependent manner, ox-LDL decreased ecNOS mRNA and protein levels (91±4% and 67±8% reduction after 72 hours, respectively). Both simvastatin (1 μmol/L) and lovastatin (10 μmol/L) upregulated ecNOS expression by 3.8-fold and 3.6-fold, respectively, and completely prevented its downregulation by ox-LDL. These effects of simvastatin on ecNOS expression correlated with changes in ecNOS activity. Although l -mevalonate alone did not affect ecNOS expression, cotreatment with l -mevalonate completely reversed ecNOS upregulation by simvastatin. Actinomycin D studies revealed that simvastatin stabilized ecNOS mRNA (τ 1/2 , 43 versus 35 hours). Nuclear run-on assays and transient transfection studies with a −1.6 kb ecNOS promoter construct showed that simvastatin did not affect ecNOS gene transcription. Conclusions —Inhibition of endothelial HMG CoA reductase upregulates ecNOS expression predominantly by posttranscriptional mechanisms. These findings suggest that HMG CoA reductase inhibitors may have beneficial effects in atherosclerosis beyond that attributed to the lowering of serum cholesterol by increasing ecNOS activity.Keywords
This publication has 19 references indexed in Scilit:
- Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen.JCI Insight, 1995
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Beneficial Effects of Cholesterol-Lowering Therapy on the Coronary Endothelium in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1995
- Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatinThe Lancet, 1994
- Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductaseThe American Journal of Cardiology, 1994
- Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with HypercholesterolemiaNew England Journal of Medicine, 1990
- Biosynthesis and Metabolism of Endothelium-Derived Nitric OxideAnnual Review of Pharmacology and Toxicology, 1990
- Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.JCI Insight, 1989
- Effects of a Competitive Inhibitor (Mevinolin) of 3‐Hydroxy‐3‐methylglutaryl Coenzyme A Reductase on Human and Bovine Endothelial Cells, Fibroblasts and Smooth Muscle Cells in VitroBasic & Clinical Pharmacology & Toxicology, 1989
- A simple fluorometric assay for lipoperoxide in blood plasmaBiochemical Medicine, 1976